EDAP TMS S.A. (FOCL) vs Outset Medical (OM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
EDAP TMS S.A. (FOCL) has outperformed Outset Medical (OM) over the past year, gaining 13.5% versus a loss of 34.5%. Over five years, FOCL leads with a -53.0% price change compared with -99.6% for OM. EDAP TMS S.A. is the larger company by market cap ($123.2 million vs $53.0 million), about 2.3 times the size, while Outset Medical is growing revenue faster (+5.1% vs +1.6%).
EDAP TMS S.A. converts more of its revenue into profit, with a net margin of -41.5% versus -68.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FOCL | OM |
|---|---|---|
| Share price | $2.61 | $2.81 |
| Market cap | $123.25M | $53.03M |
| 1-day change | -7.45% | -3.44% |
| YTD return | -20.67% | -24.26% |
| 1-year return | +13.48% | -34.50% |
| 5-year return | -52.97% | -99.61% |
| EPS (TTM) | $-1.35 | $-3.78 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $70.53M | $119.48M |
| Revenue growth (YoY) | +1.63% | +5.09% |
| Net income (latest FY) | $-29.25M | $-81.65M |
| Gross margin | 42.54% | 39.13% |
| Operating margin | -35.01% | -55.83% |
| Net margin | -41.47% | -68.34% |
| 52-week high | $6.40 | $6.49 |
| 52-week low | $2.11 | $2.77 |
| Distance from 52-week high | -59.22% | -56.70% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +218.01% | +172.95% |
| Average volume | 137.30K | 140.40K |
| Shares outstanding | 47.22M | 18.87M |
| Employees | 289 | 310 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EDAP TMS S.A. is about 2.3 times larger than Outset Medical by market value ($123.25M vs $53.03M).
- FOCL has outperformed OM by 48.0 percentage points over the past year.
- EDAP TMS S.A. is more profitable, keeping -41.5 cents of every revenue dollar as net income versus -68.3 cents for Outset Medical.
About EDAP TMS S.A.
FOCL stock →EDAP TMS S.A., doing business as FocalTherics, operates as a medical technology company that develops, manufactures, markets, and sells non-invasive therapeutic ultrasound and energy-based medical devices in Asia, France, the United States, and internationally. The company develops, manufactures, markets, and distributes non-invasive robotic HIFU systems for urology-related and other indications.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 289 employees
About Outset Medical
OM stock →Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company provides Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 310 employees
FOCL vs OM FAQ
Which is bigger, EDAP TMS S.A. or Outset Medical?
EDAP TMS S.A. (FOCL) is larger, with a market capitalization of $123.25M compared with $53.03M for Outset Medical (OM).
Which stock has performed better over the past year, FOCL or OM?
FOCL returned +13.48% over the past 12 months, compared with -34.50% for OM (price return, excluding dividends). Past performance does not predict future results.
Are EDAP TMS S.A. and Outset Medical in the same industry?
Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.